THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 110 filers reported holding THERAVANCE BIOPHARMA INC in Q4 2019. The put-call ratio across all filers is 2.28 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $15,892,663 | -6.4% | 1,841,560 | +12.3% | 3.92% | -2.2% |
| Q2 2023 | $16,978,720 | +2.2% | 1,640,456 | +7.1% | 4.01% | +22.9% |
| Q1 2023 | $16,611,513 | +2.1% | 1,531,015 | +5.6% | 3.26% | -2.8% |
| Q4 2022 | $16,269,000 | -35.7% | 1,450,000 | -41.9% | 3.36% | -39.6% |
| Q3 2022 | $25,308,000 | +37.1% | 2,495,860 | +22.5% | 5.56% | +58.8% |
| Q2 2022 | $18,463,000 | +40.5% | 2,037,825 | +48.2% | 3.50% | +11.1% |
| Q1 2022 | $13,145,000 | +19.0% | 1,375,000 | +37.5% | 3.15% | +7.3% |
| Q4 2021 | $11,050,000 | +1424.1% | 1,000,000 | +920.9% | 2.93% | +1419.7% |
| Q3 2021 | $725,000 | -83.8% | 97,955 | -43.5% | 0.19% | -53.4% |
| Q4 2019 | $4,487,000 | +261.6% | 173,300 | +172.1% | 0.41% | +253.8% |
| Q3 2019 | $1,241,000 | – | 63,681 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Link Fund Solutions Ltd | 5,251,349 | $135,459,000 | 69.86% |
| Chescapmanager LLC | 949,006 | $24,570,000 | 3.61% |
| Baupost Group | 9,309,168 | $241,014,000 | 2.66% |
| Rock Springs Capital Management LP | 655,200 | $16,963,000 | 0.54% |
| Rubric Capital Management LP | 173,400 | $4,489,000 | 0.51% |
| Newtyn Management, LLC | 173,300 | $4,487,000 | 0.41% |
| NJ State Employees Deferred Compensation Plan | 38,142 | $988,000 | 0.17% |
| King Wealth Management Group | 22,500 | $583,000 | 0.15% |
| Virtus ETF Advisers LLC | 29,216 | $756,000 | 0.12% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 452,615 | $11,718,000 | 0.12% |